HUMA

Nasdaq

Humacyte, Inc.

Latest disclosureOctober 7, 2026

Insider score Why 25?: 25/ 100
Qualifying buys · 30d: $5.62K

5 purchases · 2 sales

Price by TradingView

Insider transactions 20

Limited filing history

Filters

Last 30 daysInsiders bought $5.62K · 1 buyer, led by Keith Anthony Jones (Director) with $5.62K. No qualifying insider sales.

Sale disclosed

Dale A. Sander

CFO and Chief Corp. Dev. Off

Common Stock

Reported value: $41.15K
Reported price: $0.8967 / share

Sale disclosed

Shamik J. Parikh

Chief Medical Officer

Common Stock

Reported value: $41.15K
Reported price: $0.8967 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
CFO and Chief Corp. Dev. Off	Common StockSale10b5-1	45,887$0.90 / share	$41.15K	May 18Filed May 20 · 2d later	SEC filing
Chief Medical Officer	Common StockSale10b5-1	45,887$0.90 / share	$41.15K	May 18Filed May 20 · 2d later	SEC filing

Congress transactions 5

All Congress filings

Partial sale disclosedAmended report

Humacyte, Inc. - Common Stock · Stock

The filing reports a partial sale for a joint account.

Thomas H TubervilleReporting Senate member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: May 3, 2024

Full sale disclosedAmended report

Humacyte, Inc. - Common Stock · Stock

The filing reports a full sale for a joint account.

Thomas H TubervilleReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: May 3, 2024

Purchase disclosedAmended report

Humacyte Inc · Stock

The filing reports a purchase for a joint account.

Thomas H TubervilleReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 21, 2024

Purchase disclosedAmended report

Humacyte, Inc. - Common Stock · Stock

The filing reports a purchase for a joint account.

Thomas H TubervilleReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 21, 2024

Purchase disclosedAmended report

Humacyte, Inc. - Common Stock · Stock

The filing reports a purchase for a joint account.

Thomas H TubervilleReporting Senate member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: March 21, 2024

Why this buying score?

Qualifying common-equity purchase value

$38,580 of common-equity purchase value after transaction-age decay across 180 days.

+6 pts

Distinct buying groups

3 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+10 pts

Material reported holdings increase

At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.

+9 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001818382
Latest public acceptance: Oct 7, 2026, 08:06 PM UTC
Score calculated: Oct 8, 2026, 12:09 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

CFO and Chief Corp. Dev. Off

Common StockSale10b5-1

45,887$0.90 / share

$41.15K

May 18Filed May 20 · 2d later

SEC filing

Chief Medical Officer

Common StockSale10b5-1

45,887$0.90 / share

$41.15K

May 18Filed May 20 · 2d later

SEC filing

Why this buying score?

Qualifying common-equity purchase value

$38,580 of common-equity purchase value after transaction-age decay across 180 days.

+6 pts

Distinct buying groups

3 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.

+10 pts

Material reported holdings increase

At least one row increased reported same-security holdings by 10% or established a new reported position; indirect interests may overlap.

+9 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001818382
Latest public acceptance: Oct 7, 2026, 08:06 PM UTC
Score calculated: Oct 8, 2026, 12:09 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.